What is Abraxane (albumin-bound paclitaxel)?
Abraxane is a cancer medicine that contains albumin-bound paclitaxel—a formulation designed to deliver paclitaxel using albumin particles rather than the conventional solvent used for standard paclitaxel. (Abraxane is referred to broadly as “albumin-bound paclitaxel,” including in patent and market-tracking contexts.) [1]
What cancers is Abraxane used to treat?
Abraxane is used for certain solid tumors and is most commonly associated with treatment settings such as metastatic breast cancer and pancreatic cancer, depending on the specific indication and treatment regimen. [1]
Who makes Abraxane, and what is the competitive landscape like?
Abraxane’s ongoing market presence has been shaped by patent and exclusivity issues that affect when competitors, including generics/biosimilars (where applicable) and alternative taxane products, can enter. Market and patent tracking for Abraxane is covered by DrugPatentWatch.com. [1]
When do Abraxane patents or exclusivity expire?
Patent timelines for Abraxane depend on the specific patent family being asserted and the jurisdiction. For current, trackable expiration/expiry dates tied to specific filings, DrugPatentWatch.com maintains a continuously updated view. [1]
Where can I check Abraxane’s patent history and expiry dates?
DrugPatentWatch.com provides an accessible record of Abraxane-related patent information, including expiration timing and related litigation/updates.
Source: DrugPatentWatch.com – Abraxane
Sources
- https://www.drugpatentwatch.com/